Background Infectious keratitis (IK) is one of the major causes of corneal blindness in developing and developed nations. Numerous infections, including bacterial, fungal, viral, and protozoa, have been linked to IK. Corneal perforations can happen as one of the complications of IK. In this study, we aim to determine the clinical and microbiological profile and to study the treatment outcomes of IK. Material and methods It is a prospective, observational, and experimental study conducted in a tertiary care hospital and research center in Western Maharashtra, India, from September 2022 to June 2024. The sample size was 107 patients with IK. All patients were above 15 years of age, and all cases of microbial keratitis were within the inclusion criteria. Patients less than 15 years of age, patients with any other associated corneal pathology, healed cases of infectious keratitis, peripheral ulcerative keratitis, patients not willing to participate in the study, or not giving consent were excluded. Patients were examined thoroughly, and corneal scraping samples were collected and sent for microbiological examination. Appropriate treatment was provided through medical or surgical management, and treatment outcomes were evaluated during frequent follow-up visits. Results In our study, the majority of patients originated from rural areas, with most being over 60 years of age. Diabetes mellitus was seen in 24.3%, and a history of ocular trauma was present in 48.5% of patients. (3.74%) was the most common organism seen on gram staining, followed by (2.8%). was the only gram-negative organism seen. The number of patients who had fungal isolates positive on culture was 57%, 12.1% had bacterial, and 30% had no growth of microorganisms. species were seen in 39.2% of culture isolates, followed by and in 7.47% each. In 96% of medically managed patients, ulcers healed within two months. All ulcers with severe and moderate depth required therapeutic penetrating keratoplasty. A graft was in place in 95.2% after therapeutic penetrating keratoplasty, while one patient had graft rejection, and in one patient, endophthalmitis was seen. Conclusion was the most common bacterial agent isolated on gram staining, and was the only gram-negative bacillus isolated on gram staining. Fungal isolates were the most common isolates observed on culture, seen in more than half of the IK patients in our study. The majority of patients who underwent medical management had ulcers healed in two months. The majority of the patients who underwent surgical management had fungal isolates positive. We recommend further research to be conducted in a generalized population, including urban settings, to understand the risk factors, microbiological profile, and treatment outcomes for IK.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11548677 | PMC |
http://dx.doi.org/10.7759/cureus.71160 | DOI Listing |
Lung Cancer
December 2024
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Background: The upfront treatment of non-oncogene-addicted NSCLC relies on immunotherapy alone (ICI) or in combination with chemotherapy (CT-ICI). Genomic aberrations such as KRAS, TP53, KEAP1, SMARCA4, or STK11 may impact survival outcomes.
Methods: We performed an observational study of 145 patients treated with first-line IO or CT-ICI for advanced non-squamous (nsq) NSCLC at our institution tested with an extensive lab-developed NGS panel.
Leuk Lymphoma
December 2024
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Over the past two decades, new agents for multiple myeloma (MM) have significantly improved patient outcomes, particularly for those with standard-risk disease, who now have a median overall survival of over a decade. However, this benefit is less pronounced in high-risk and ultra-high-risk MM, where median survival ranges from 3 to 5 years. The definition of HRMM continues to evolve and is driven by the genomic features, disease burden, and medical comorbidities.
View Article and Find Full Text PDFExpert Opin Pharmacother
December 2024
Department of Metabolic Medicine/Chemical Pathology Guy's & St Thomas' Hospitals, London, UK.
Introduction: Lipid-lowering therapies are well established for the treatment of cardiovascular disease (CVD). Historically monotherapy studies were performed but the introduction of statins has led to these drugs being recognized as baseline therapies and to the investigation of combination therapy of both older and newer medications with them.
Areas Covered: Surrogate marker studies have shown additive effects on LDL-C, triglycerides and HDL-C of combination therapies with statins and these have extended to lipoprotein (a).
STAR Protoc
December 2024
University Lille, Inserm, CHU Lille, U1192 - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, F-59000 Lille, France; Equipe Labellisée Ligue Contre le Cancer, Lille, France. Electronic address:
Cancer progression and treatment outcomes are heavily influenced by the tumor microenvironment (TME), especially through immune cell interactions. Here, we present a protocol for generating co-cultures of tumoroids with macrophages, either semi-liquid or Matrigel-embedded. We describe steps for macrophage preparation, co-culture establishment, and medium adjustments to support cell viability and function.
View Article and Find Full Text PDFAge Ageing
November 2024
Department of Physical Education and Sport, Faculty of Sport Sciences, University of Granada, Granada, Spain.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!